Induction of VEGF by tepoxalin does not lead to increased tumour growth in a canine osteosarcoma xenograft

Veterinary and Comparative Oncology

Volumn 9, Issue 2, 2011, Pages 118-130

  Sottnik, J L ^a   Hansen, R J ^a   Gustafson, D L ^a   Dow, S W ^a   Thamm, D H ^a  

^a Veterinary Dentistry and Oral Surgery   (United States)

Author keywords

Angiogenesis; Hypoxia inducible factor 1; Mouse; Non steroidal anti inflammatory drug

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 1ALPHA; NONSTEROID ANTIINFLAMMATORY AGENT; PYRAZOLE DERIVATIVE; TEPOXALIN; VASCULOTROPIN;

ANIMAL; ANIMAL DISEASE; ARTICLE; BONE TUMOR; CELL PROLIFERATION; DOG; DOG DISEASE; DRUG EFFECT; IN VITRO STUDY; MALE; METABOLISM; MOUSE; OSTEOSARCOMA; PATHOLOGY; TUMOR VOLUME; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOTTING, WESTERN; BONE NEOPLASMS; CELL PROLIFERATION; DOG DISEASES; DOGS; HYPOXIA-INDUCIBLE FACTOR 1, ALPHA SUBUNIT; MALE; MICE; OSTEOSARCOMA; PYRAZOLES; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN; VASCULAR ENDOTHELIAL GROWTH FACTORS;

CANIS FAMILIARIS;

EID: 79956011942     PISSN: 14765810     EISSN: 14765829     Source Type: Journal    
DOI: 10.1111/j.1476-5829.2010.00240.x     Document Type: Article

References (57)

1. Merlo DF, Rossi L, Pellegrino C, Ceppi M, Cardellino U, Capurro C, Ratto A, Sambucco PL, Sestito V, Tanara G and Bocchini V. Cancer incidence in pet dogs: findings of the Animal Tumor Registry of Genoa, Italy. Journal of Veterinary Internal Medicine 2008; 22: 976-984.
2. Smith GK, Paster ER, Powers MY, Lawler DF, Biery DN, Shofer FS, McKelvie PJ and Kealy RD. Lifelong diet restriction and radiographic evidence of osteoarthritis of the hip joint in dogs. Journal of the American Veterinary Medical Association 2006; 229: 690-693.
3. Agnello KA, Reynolds LR and Budsberg SC. In vivo effects of tepoxalin, an inhibitor of cyclooxygenase and lipoxygenase, on prostanoid and leukotriene production in dogs with chronic osteoarthritis. American Journal of Veterinary Research 2005; 66: 966-972.
4. Argentieri DC, Ritchie DM, Ferro MP, Kirchner T, Wachter MP, Anderson DW, Rosenthale ME and Capetola RJ. Tepoxalin: a dual cyclooxygenase/ 5-lipoxygenase inhibitor of arachidonic acid metabolism with potent anti-inflammatory activity and a favorable gastrointestinal profile. Journal of Pharmacology and Experimental Therapeutics 1994; 271: 1399-1408.
5. Dhawan D, Jeffreys AB, Zheng R, Stewart JC and Knapp DW. Cyclooxygenase-2 dependent and independent antitumor effects induced by celecoxib in urinary bladder cancer cells. Molecular Cancer Therapeutics 2008; 7: 897-904.
6. Fiebich BL, Hofer TJ, Lieb K, Huell M, Butcher RD, Schumann G, Schulze-Osthoff K and Bauer J. The non-steroidal anti-inflammatory drug tepoxalin inhibits interleukin-6 and alpha1-anti- chymotrypsin synthesis in astrocytes by preventing degradation of IkappaB-alpha. Neuropharmacology 1999; 38: 1325-1333.
7. Heller DA, Fan TM, de Lorimier LP, Charney SC, Barger AM, Tannehill-Gregg SH, Rosol TJ and Wallig MA. In vitro cyclooxygenase-2 protein expression and enzymatic activity in neoplastic cells. Journal of Veterinary Internal Medicine 2007; 21: 1048-1055.
8. Mullins MN, Lana SE, Dernell WS, Ogilvie GK, Withrow SJ and Ehrhart EJ. Cyclooxygenase-2 expression in canine appendicular osteosarcomas. Journal of Veterinary Internal Medicine 2004; 18: 859-865.
9. Sabino MA, Ghilardi JR, Jongen JL, Keyser CP, Luger NM, Mach DB, Peters CM, Rogers SD, Schwei MJ, de Felipe C and Mantyh PW. Simultaneous reduction in cancer pain, bone destruction, and tumor growth by selective inhibition of cyclooxygenase-2. Cancer Research 2002; 62: 7343-7349.
10. Sigthorsson G, Simpson RJ, Walley M, Anthony A, Foster R, Hotz-Behoftsitz C, Palizban A, Pombo J, Watts J, Morham SG and Bjarnason I. COX-1 and 2, intestinal integrity, and pathogenesis of nonsteroidal anti-inflammatory drug enteropathy in mice. Gastroenterology 2002; 122: 1913-1923.
11. Whittle BJ. Mechanisms underlying intestinal injury induced by anti-inflammatory COX inhibitors. European Journal of Pharmacology 2004; 500: 427-439.
12. Ding XZ, Iversen P, Cluck MW, Knezetic JA and Adrian TE. Lipoxygenase inhibitors abolish proliferation of human pancreatic cancer cells. Biochemical Biophysical Research Communications 1999; 261: 218-223.
13. Ghosh J and Myers CE. Inhibition of arachidonate 5-lipoxygenase triggers massive apoptosis in human prostate cancer cells. Proceedings of the National Academy of Sciences of the United States of America 1998; 95: 13182-13187.
14. Melstrom LG, Bentrem DJ, Salabat MR, Kennedy TJ, Ding XZ, Strouch M, Rao SM, Witt RC, Ternent CA, Talamonti MS, Bell RH and Adrian TA. Overexpression of 5-lipoxygenase in colon polyps and cancer and the effect of 5-LOX inhibitors in vitro and in a murine model. Clinical Cancer Research 2008; 14: 6525-6530.
15. Charlier C and Michaux C. Dual inhibition of cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) as a new strategy to provide safer non-steroidal anti-inflammatory drugs. European Journal of Medicinal Chemistry 2003; 38: 645-659.
16. Fusellier M, Desfontis JC, Madec S, Gautier F, Marescaux L, Debailleul M and Gogny M. Effect of tepoxalin on renal function in healthy dogs receiving an angiotensin-converting enzyme inhibitor. Journal of Veterinary Pharmacology and Therapeutics 2005; 28: 581-586.
17. Goodman L, Torres B, Punke J, Reynolds L, Speas A, Ellis A and Budsberg S. Effects of firocoxib and tepoxalin on healing in a canine gastric mucosal injury model. Journal of Veterinary Internal Medicine 2009; 23: 56-62.
18. Punke JP, Speas AL, Reynolds LR and Budsberg SC. Effects of firocoxib, meloxicam, and tepoxalin on prostanoid and leukotriene production by duodenal mucosa and other tissues of osteoarthritic dogs. American Journal of Veterinary Research 2008; 69: 1203-9.
19. Wallace JL, McCafferty DM, Carter L, McKnight W and Argentieri D. Tissue-selective inhibition of prostaglandin synthesis in rat by tepoxalin: anti-inflammatory without gastropathy?. Gastroenterology 1993; 105: 1630-1636.
20. Zhou L, Ritchie D, Wang EY, Barbone AG, Argentieri D and Lau CY. Tepoxalin, a novel immunosuppressive agent with a different mechanism of action from cyclosporin A. Journal of Immunology 1994; 153: 5026-5037.
21. Kazmi SM, Plante RK, Visconti V, Taylor GR, Zhou L and Lau CY. Suppression of NF kappa B activation and NF kappa B-dependent gene expression by tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase. Journal of Cellular Biochemistry 1995; 57: 299-310.
22. Ritchie DM, Argentieri DC, Aparicio BL, Plante RK, Lau CY and Barbone AG. Cytokine-modulating activity of tepoxalin, a new potential antirheumatic. International Journal of Immunopharmacology 1995; 17: 805-812.
23. Tam SS, Lee DH, Wang EY, Munroe DG and Lau CY. Tepoxalin, a novel dual inhibitor of the prostaglandin-H synthase cyclooxygenase and peroxidase activities. Journal of Biological Chemistry 1995; 270: 13948-13955.
24. Iwata C, Kano MR, Komuro A, Oka M, Kiyono K, Johansson E, Morishita Y, Yashiro M, Hirakawa K, Kaminishi M and Miyazono K. Inhibition of cyclooxygenase-2 suppresses lymph node metastasis via reduction of lymphangiogenesis. Cancer Research 2007; 67: 10181-10189.
25. Bouck N, Stellmach V and Hsu SC. How tumors become angiogenic. Advances in Cancer Research 1996; 69: 135-174.
26. Folkman J. Tumor angiogenesis: a possible control point in tumor growth. Annals of Internal Medicine 1975; 82: 96-100.
27. Hanahan D and Weinberg RA. The hallmarks of cancer. Cell 2000; 100: 57-70.
28. Angelo LS and Kurzrock R. Vascular endothelial growth factor and its relationship to inflammatory mediators. Clinical Cancer Research 2007; 13: 2825-2830.
29. Patiar S and Harris AL. Role of hypoxia-inducible factor-1alpha as a cancer therapy target. Endocrine-Related Cancer 2006; 13 (Suppl. 1): S61-S75.
30. Shchors K and Evan G. Tumor angiogenesis: cause or consequence of cancer?. Cancer Research 2007; 67: 7059-61.
31. Knight EV, Kimball JP, Keenan CM, Smith IL, Wong FA, Barrett DS, Dempster AM, Lieuallen WG, Panigrahi D, Powers WJ and Szot RJ. Preclinical toxicity evaluation of tepoxalin, a dual inhibitor of cyclooxygenase and 5-lipoxygenase, in Sprague-Dawley rats and beagle dogs. Fundamental and Applied Toxicology 1996; 33: 38-48.
32. Homer LM, Clarke CR and Weingarten AJ. Effect of dietary fat on oral bioavailability of tepoxalin in dogs. Journal of Veterinary Pharmacology and Therapeutics 2005; 28: 287-291.
33. Burinsky DJ, Armstrong BL, Oyler AR and Dunphy R. Characterization of tepoxalin and its related compounds by high-performance liquid chromatography/mass spectrometry. Journal of Pharmaceutical Sciences 1996; 85: 159-64.
34. Sica A, Rubino L, Mancino A, Larghi P, Porta C, Rimoldi M, Solinas G, Locati M, Allavena P and Mantovani A. Targeting tumour-associated macrophages. Expert Opinion on Therapeutic Targets 2007; 11: 1219-1229.
35. Wang GL and Semenza GL. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 1993; 82: 3610-3615.
36. Iizuka M, Yamauchi M, Ando K, Hori N, Furusawa Y, Itsukaichi H, Fukutsu K and Moriya H. Quantitative RT-PCR assay detecting the transcriptional induction of vascular endothelial growth factor under hypoxia. Biochemical Biophysical Research Communications 1994; 205: 1474-1480.
37. Buchanan FG, Holla V, Katkuri S, Matta P and DuBois RN. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer. Cancer Research 2007; 67: 9380-9388.
38. Mustafa A and Kruger WD. Suppression of tumor formation by a cyclooxygenase-2 inhibitor and a peroxisome proliferator-activated receptor gamma agonist in an in vivo mouse model of spontaneous breast cancer. Clinical Cancer Research 2008; 14: 4935-4942.
39. Ping YF, Yao XH, Chen JH, Liu H, Chen DL, Zhou XD, Wang JM and Bian XW. The anti-cancer compound Nordy inhibits CXCR4-mediated production of IL-8 and VEGF by malignant human glioma cells. Journal of Neurooncology 2007; 84: 21-29.
40. Mohammed SI, Bennett PF, Craig BA, Glickman NW, Mutsaers AJ, Snyder PW, Widmer WR, DeGortari AE, Bonney PL and Knapp DW. Effects of the cyclooxygenase inhibitor, piroxicam, on tumor response, apoptosis, and angiogenesis in a canine model of human invasive urinary bladder cancer. Cancer Research 2002; 62: 356-358.
41. Royals SR, Farese JP, Milner RJ, Lee-Ambrose L and van Gilder J. Investigation of the effects of deracoxib and piroxicam on the in vitro viability of osteosarcoma cells from dogs. American Journal of Veterinary Research 2005; 66: 1961-1967.
42. Harris RE, Beebe-Donk J and Alshafie GA. Reduction in the risk of human breast cancer by selective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2006; 6: 27.
43. Harris RE, Beebe-Donk J and Alshafie GA. Similar reductions in the risk of human colon cancer by selective and nonselective cyclooxygenase-2 (COX-2) inhibitors. BMC Cancer 2008; 8: 237.
44. Schroeder CP, Yang P, Newman RA and Lotan R. Simultaneous inhibition of COX-2 and 5-LOX activities augments growth arrest and death of premalignant and malignant human lung cell lines. Journal of Experimental Therapeutics and Oncology 2007; 6: 183-192.
45. Tavolari S, Bonafe M, Marini M, Ferreri C, Bartolini G, Brighenti E, Manara S, Tomasi V, Laufer S and Guarnieri T. Licofelone, a dual COX/5-LOX inhibitor, induces apoptosis in HCA-7 colon cancer cells through the mitochondrial pathway independently from its ability to affect the arachidonic acid cascade. Carcinogenesis 2008; 29: 371-380.
46. Choi CH, Song SY, Choi JJ, Ae Park Y, Kang H, Kim TJ, Lee JW, Kim BG, Lee JH and Bae DS. Prognostic significance of VEGF expression in patients with bulky cervical carcinoma undergoing neoadjuvant chemotherapy. BMC Cancer 2008; 8: 295.
47. Thamm DH, O'Brien MG and Vail DM. Serum vascular endothelial growth factor concentrations and postsurgical outcome in dogs with osteosarcoma. Veterinary and Comparative Oncology 2008; 6: 126-132.
48. Wergin MC and Kaser-Hotz B. Plasma vascular endothelial growth factor (VEGF) measured in seventy dogs with spontaneously occurring tumours. In Vivo 2004; 18: 15-19.
49. Stewart GD, Nanda J, Brown DJ, Riddick AC, Ross JA and Habib FK. NO-sulindac inhibits the hypoxia response of PC-3 prostate cancer cells via the Akt signalling pathway. International Journal of Cancer 2008; 124: 223-232.
50. Crokart N, Radermacher K, Jordan BF, Baudelet C, Cron GO, Gregoire V, Beghein N, Bouzin C, Feron O and Gallez B. Tumor radiosensitization by antiinflammatory drugs: evidence for a new mechanism involving the oxygen effect. Cancer Research 2005; 65: 7911-7916.
51. Lee DH, Tam SS, Wang E, Taylor GR, Plante RK and Lau CY. The NF-kappa B inhibitor, tepoxalin, suppresses surface expression of the cell adhesion molecules CD62E, CD11b/CD18 and CD106. Immunology Letters 1996; 53: 109-113.
52. Panes J, Molla M, Casadevall M, Salas A, Sans M, Conill C, Anderson DC, Rosello-Catafau J, Granger DN and Pique JM. Tepoxalin inhibits inflammation and microvascular dysfunction induced by abdominal irradiation in rats. Alimentary Pharmacology and Therapeutics 2000; 14: 841-850.
53. Zhou L, Pope BL, Chourmouzis E, Fung-Leung WP and Lau CY. Tepoxalin blocks neutrophil migration into cutaneous inflammatory sites by inhibiting Mac-1 and E-selectin expression. European Journal of Immunology 1996; 26: 120-129.
54. Bertolini F, Shaked Y, Mancuso P and Kerbel RS. The multifaceted circulating endothelial cell in cancer: towards marker and target identification. Nature Reviews Cancer 2006; 6: 835-845.
55. Gao D, Nolan DJ, Mellick AS, Bambino K, McDonnell K and Mittal V. Endothelial progenitor cells control the angiogenic switch in mouse lung metastasis. Science 2008; 319: 195-198.
56. Lewis CE and Pollard JW. Distinct role of macrophages in different tumor microenvironments. Cancer Research 2006; 66: 605-612.
57. Martinez FO, Sica A, Mantovani A and Locati M. Macrophage activation and polarization. Frontiers in Bioscience 2008; 13: 453-461.